Rheinfelden, Switzerland

Thomas Knoepfel

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 8.3

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Rheinfelden, CH (2018 - 2020)
  • Basel, CH (2021)

Company Filing History:


Years Active: 2018-2021

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: The Innovative Path of Thomas Knoepfel: A Pioneer in Pharmaceutical Inventions

Introduction

Thomas Knoepfel, an accomplished inventor based in Rheinfelden, Switzerland, has made significant contributions to the pharmaceutical field. With a total of four patents to his name, Knoepfel has focused on developing innovative solutions to combat autoimmune diseases through cutting-edge compositions and compounds.

Latest Patents

Among his most notable work are two recent patents. The first, titled "Compounds and compositions as inhibitors of endosomal toll-like receptors," involves the invention of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds. This invention not only details pharmaceutical compositions that utilize these compounds but also emphasizes their utility in treating autoimmune diseases. The second patent, "Formylated N-heterocyclic derivatives as FGFR4 inhibitors," introduces a compound defined by formula (I) or its pharmaceutically acceptable salts. This invention also includes methods for manufacturing the compound and outlines its therapeutic uses along with combinations of pharmacologically active agents.

Career Highlights

Currently, Thomas Knoepfel is employed at Novartis AG, where his expertise significantly contributes to the company's mission of addressing critical health challenges through innovative therapies. His work at Novartis highlights his commitment to advancing medicine and improving patient outcomes.

Collaborations

Throughout his career, Knoepfel has collaborated with talented colleagues including Nicole Buschmann and Robin Alec Fairhurst. These partnerships reflect a collaborative spirit that is often essential in the pursuit of groundbreaking innovations in pharmaceuticals.

Conclusion

Thomas Knoepfel exemplifies the spirit of innovation within the pharmaceutical industry. With his focused efforts on developing novel compounds and compositions, he is paving the way for future advancements in the treatment of autoimmune diseases. His contributions, supported by collaboration and a commitment to excellence at Novartis AG, ensure that he remains a key figure in the journey of pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…